Literature DB >> 7744089

Percutaneous balloon pericardiostomy for treatment of cardiac tamponade.

E Di Segni1, J Lavee, E Kaplinsky, Z Vered.   

Abstract

Percutaneous balloon pericardiostomy was performed in eight severely ill patients with malignancy (seven patients) and chronic renal failure (one patient). To investigate the feasibility of balloon pericardiostomy as a bedside procedure, echocardiography was used in addition to fluoroscopy in monitoring the procedure. The pericardium was entered from the standard subxiphoid site. An 18 to 25 mm, 3 or 4 cm long, balloon catheter, introduced over a stiff guidewire was inflated across the parietal pericardium. Creation of a pericardial opening was obtained in each of the eight patients. Bleeding from the needle entry site was the only complication observed in one patient. The balloon catheter could be localized by echocardiography only in 2/8 cases. Two patients died, 3 and 14 days after the procedure, from the primary disease; six patients were still alive at follow-up ranging from 32 to 342 days. No recurrence of cardiac tamponade was observed in any patient. Percutaneous balloon pericardiostomy is efficacious and safe in relieving pericardial tamponade and preventing its recurrence in severely ill patients. Fluoroscopy is needed to monitor the procedure. The value of echocardiography is limited for follow-up controls of pericardial effusion.

Entities:  

Mesh:

Year:  1995        PMID: 7744089     DOI: 10.1093/oxfordjournals.eurheartj.a060883

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  2 in total

Review 1.  Modern approaches and use of surgical treatment for pericardial disease.

Authors:  Edward P Chen; Joseph I Miller
Journal:  Curr Cardiol Rep       Date:  2002-01       Impact factor: 2.931

2.  Comparison of surgical pericardial drainage with percutaneous catheter drainage for pericardial effusion.

Authors:  Adam J Saltzman; Yehuda E Paz; A Garvey Rene; Philip Green; Ahmed Hassanin; Michael G Argenziano; Leroy Rabbani; George Dangas
Journal:  J Invasive Cardiol       Date:  2012-11       Impact factor: 2.022

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.